$1.52
+0.04 (+2.70%)
Open$1.49
Previous Close$1.48
Day High$1.61
Day Low$1.49
52W High$26.28
52W Low$16.46
Volume—
Avg Volume493.4K
Market Cap92.56M
P/E Ratio23.81
EPS$0.94
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,673.7% upside
Current
$1.52
$1.52
Target
$26.96
$26.96
$18.17
$26.96 avg
$35.46
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 35.55M | 33.75M | 28.19M |
| Net Income | 3.58M | 3.41M | 3.47M |
| Profit Margin | 10.1% | 10.1% | 12.3% |
| EBITDA | 5.92M | 5.34M | 5.16M |
| Free Cash Flow | 3.84M | 3.54M | 2.49M |
| Rev Growth | -9.4% | +19.8% | -2.2% |
| Debt/Equity | 0.12 | 0.13 | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |